Show simple item record

dc.contributor.authorMelero, Jose Antonio 
dc.contributor.authorMoore, Martin L
dc.identifier.citationCurr Top Microbiol Immunol. 2013;372:59-82. doi: 10.1007/978-3-642-38919-1_3.es_ES
dc.description.abstractMolecular epidemiology studies have provided convincing evidence of antigenic and sequence variability among respiratory syncytial virus (RSV) isolates. Circulating viruses have been classified into two antigenic groups (A and B) that correlate with well-delineated genetic groups. Most sequence and antigenic differences (both inter- and intra-groups) accumulate in two hypervariable segments of the G-protein gene. Sequences of the G gene have been used for phylogenetic analyses. These studies have shown a worldwide distribution of RSV strains with both local and global replacement of dominant viruses with time. Although data are still limited, there is evidence that strain variation may contribute to differences in pathogenicity. In addition, there is some but limited evidence that RSV variation may be, at least partially, immune (antibody) driven. However, there is the paradox in RSV that, in contrast to other viruses (e.g., influenza viruses) the epitopes recognized by the most effective RSV-neutralizing antibodies are highly conserved. In contrast, antibodies that recognize strain-specific epitopes are poorly neutralizing. It is likely that this apparent contradiction is due to the lack of a comprehensive knowledge of the duration and specificities of the human antibody response against RSV antigens. Since there are some data supporting a group- (or clade-) specific antibody response after a primary infection in humans, it may be wise to consider the incorporation of strains representative of groups A and B (or their antigens) in future RSV vaccine development.es_ES
dc.description.sponsorshipWork in the Madrid laboratory is currently funded by grants GR09/0039 from Instituto de Salud Carlos III and SAF2009-11632 and SAF2012-31217 from Plan Nacional de I+D+i. Work in the Atlanta laboratory is supported by the following grants: NIH 1R01AI087798 and NIH 1U19AI095227.es_ES
dc.publisherSpringer Verlages_ES
dc.subject.meshAntibodies, Viral es_ES
dc.subject.meshAntibody Specificity es_ES
dc.subject.meshAntigenic Variation es_ES
dc.subject.meshAntigens, Viral es_ES
dc.subject.meshEvolution, Molecular es_ES
dc.subject.meshHumans es_ES
dc.subject.meshMolecular Epidemiology es_ES
dc.subject.meshPhylogeny es_ES
dc.subject.meshRespiratory Syncytial Virus Infections es_ES
dc.subject.meshRespiratory Syncytial Virus Vaccines es_ES
dc.subject.meshRespiratory Syncytial Virus, Humanes_ES
dc.subject.meshSpecies Specificity es_ES
dc.subject.meshVaccines, Subunit es_ES
dc.subject.meshViral Fusion Proteins es_ES
dc.titleInfluence of respiratory syncytial virus strain differences on pathogenesis and immunityes_ES
dc.rights.licenseAtribución-NoComercial-CompartirIgual 4.0 Internacional*
dc.contributor.funderInstituto de Salud Carlos III - ISCIII
dc.identifier.journalCurrent topics in microbiology and immunologyes_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/NIH 1R01AI087798es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/NIH 1U19AI095227es_ES

Files in this item

Acceso Abierto

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-CompartirIgual 4.0 Internacional
This item is licensed under a: Atribución-NoComercial-CompartirIgual 4.0 Internacional